Neuroone Med Technologies Corp Stock Price, News & Analysis

NeuroOne Medical Technologies (Nasdaq: NMTC), a medical technology company focused on improving surgical care options for neurological disorders, has announced it will host a conference call and webcast on August 14, 2024, at 4:30 PM Eastern Time. The event will cover financial results for the third quarter of fiscal year 2024 ended June 30, 2024, and provide a corporate update.

The conference call will be accessible via toll-free and international numbers, with a participant access code. A phone replay will be available until August 28, 2024. Additionally, a live webcast will be provided, with the replay available for 12 months.

NeuroOne Medical Technologies (Nasdaq: NMTC) has secured $5.65 million in financing through a combination of a $2.65 million private placement and a $3 million credit facility. The private placement involved issuing 2,944,446 shares of common stock and warrants to purchase 2,208,338 additional shares at $0.90 per unit. The company also announced signing a non-binding term sheet with an undisclosed global medical technology company for the distribution of its OneRF™ Ablation System.

The funds will be used for OneRF commercialization activities, product development for a new ablation indication, and to support the company during the diligence process with a potential strategic partner. CEO Dave Rosa expressed confidence in the company's position to operate and move forward with the potential partnership, expected to close by the end of the third calendar quarter.

NeuroOne Medical Technologies (Nasdaq: NMTC) announced the successful use of its OneRF Ablation System to perform five ablations on a patient with multifocal epilepsy at a prestigious hospital in Jacksonville, Florida. This was achieved using ten Evo sEEG electrodes, which identified seizure-triggering brain areas, and targeted ablations were confirmed by post-ablation sEEG recordings. The procedure was performed at the bedside, saving time and costs associated with operating room use. The OneRF Ablation System is NeuroOne’s first therapeutic device and third FDA 510(k)-cleared device. CEO Dave Rosa highlighted the system's potential to reduce operating room usage and foresees the expansion of its applications with future FDA submissions.

NeuroOne now offers a complete line of thin film electrode technology for diagnostic brain mapping and RF ablation. The estimated brain ablation market is over $100 million worldwide and is expected to grow significantly due to unmet clinical needs.

NeuroOne announced that the CMS has approved a new ICD-10-PCS code for its OneRF™ Ablation procedure, effective October 1, 2024. This code, 00503Z4, facilitates hospital reporting of inpatient procedures using the FDA-cleared OneRF™ Ablation system, aimed at creating RF lesions for neurosurgical operations. CEO Dave Rosa highlighted that this approval is key to increasing the recognition and utilization of their technology, potentially reducing hospital stays and adverse events. NeuroOne's product portfolio includes the Evo® cortical and sEEG electrode lines for brain mapping and RF ablation, with the brain ablation market estimated to exceed $100M globally.

NeuroOne Medical Technologies (NASDAQ: NMTC) reported its financial results for Q2 FY2024, ending March 31, 2024. Product revenue increased to $1,377,000 from $466,000 in Q2 FY2023. The company raised an additional $2 million through the ATM Program. Key product updates include the commercial launch of the OneRF Ablation System and expanded use of the Evo sEEG system by Zimmer Biomet.

R&D expenses decreased to $1.3 million, while SG&A expenses rose to $2 million. Total operating expenses were $3.3 million. The net loss dropped to $2.9 million from $3.5 million in Q2 FY2023. Cash and cash equivalents fell to $2.4 million from $5.3 million as of September 2023.

Key upcoming milestones include transitioning to OneRF electrodes, enhancing the drug delivery program, and refining the spinal cord stimulation program.

NeuroOne Medical Technologies (NMTC) will host a conference call and webcast on May 14, 2024, to discuss the financial results for its second quarter of fiscal year 2024 and provide a corporate update. The company focuses on improving surgical care options and outcomes for patients with neurological disorders.